Mercia Fund Management announces first SEIS investments from the Mercia Growth Fund 1

Mercia EIS Funds | 9th April, 2013
Mercia Fund Management announces first SEIS investments from the Mercia Growth Fund 1
Mercia EIS Funds | 4th April, 2013
Oxford’s Native Antigen Company receives funding boost
Mercia EIS Funds | 27th March, 2013
Mercia Fund Management announces its first EIS investments from Mercia Growth Fund 1
Mercia EIS Funds | 25th March, 2013
Why SEIS is particularly attractive for 2013/14
Mercia EIS Funds | 15th March, 2013
Mercia Fund Management holds first Open House for SEIS and EIS investees
Mercia EIS Funds | 8th March, 2013
PolyTherics receives milestone payment as Celtic Pharma progresses development of long-acting version of Blood Factor VIII produced using PolyTherics’ TheraPEG™ technology
Mercia EIS Funds | 6th March, 2013
Mercia Fund Management launches Mercia Growth Fund 2 – a new hybrid EIS/SEIS investment opportunity
Mercia EIS Funds | 4th March, 2013
PsiOxus Therapeutics completes patient enrolment for Phase II wasting disease therapeutic MT-102
Mercia EIS Funds | 18th February, 2013
Forward Group takes equity stake in Mercia Fund Management
Mercia EIS Funds | 17th January, 2013
DTRA awards US$3.3m contract to psioxus therapeutics to develop biodefence vaccine adjuvants